MindMed

Mind Medicine Inc. is a biopharmaceutical company based in New York that focuses on discovering, developing, and deploying psychedelic-inspired medicines and therapies aimed at addressing addiction and mental health disorders. Founded in 2010 by JR Rahn, Scott Freeman, Leonard Latchman, and Stephen L. Hurst, the company is building a diverse drug development pipeline featuring innovative treatments derived from various psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative known as 18-MC. MindMed actively seeks collaborations and conducts clinical trials to explore the therapeutic potential of these substances in improving brain health and treating mental illness.